Analyzing Biotricity (NASDAQ:BTCY) & Alphatec (NASDAQ:ATEC)

Alphatec (NASDAQ:ATEC) and Biotricity (NASDAQ:BTCY) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.

Analyst Ratings

This is a summary of recent ratings and price targets for Alphatec and Biotricity, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alphatec	0	1	8	0	2.89
Biotricity	0	1	0	0	2.00

Alphatec presently has a consensus target price of $17.67, suggesting a potential upside of 64.11%. Given Alphatec’s stronger consensus rating and higher possible upside, equities analysts clearly believe Alphatec is more favorable than Biotricity.

Volatility and Risk

Alphatec has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, Biotricity has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500.

Insider & Institutional Ownership

66.3% of Alphatec shares are owned by institutional investors. Comparatively, 3.9% of Biotricity shares are owned by institutional investors. 22.8% of Alphatec shares are owned by company insiders. Comparatively, 10.1% of Biotricity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Alphatec and Biotricity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alphatec	-31.06%	-541.39%	-22.99%
Biotricity	-80.42%	N/A	-188.47%

Valuation & Earnings

This table compares Alphatec and Biotricity”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alphatec	$611.56 million	2.54	-$186.64 million	($1.14)	-9.44
Biotricity	$12.06 million	1.07	-$14.09 million	($1.08)	-0.49

Biotricity has lower revenue, but higher earnings than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.

Summary

Alphatec beats Biotricity on 10 of the 14 factors compared between the two stocks.

About Alphatec

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.